Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Ovarian Neoplasms 3Multiple Myeloma 3Lymphoma 3Urinary Bladder Neoplasms 2Lung Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Sarcoma, Synovial 1Recurrent Lung Squamous Cell Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neoplasm Metastasis 1Meningeal Neoplasms 1Melanoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Fibrolamellar hepatocellular carcinoma 1

Interventions

Cyclophosphamide 11Doxorubicin 9Vincristine 8Methotrexate 6nelarabine 5Prednisone 5Peripheral Blood Stem Cell Transplantation 5Leucovorin 5Cytarabine 5tanespimycin 4merphos 4fludarabine phosphate 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Etoposide 4Dexamethasone 4Cyclosporine 4Calcium Dobesilate 4Bortezomib 4prednylidene 3pegaspargase 3deltacortene 3azathiopurine 3Vorinostat 3Thioguanine 3Radiotherapy 3Pharmacogenomic Testing 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × sapanisertib × Clear all
NCT02484430 2025-03-03

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡